CrownBio's permanent HuKemia models allow clients to follow disease recurrence after initial treatment challenge to test the efficacy of novel agents against drug resistance. "Transient models simply provide a one-shot study, whereas we have the ability to study both efficacy against primary and relapsed disease," commented Li.
CrownBio plans to publish further papers on the latest results from the HuKemia collection in the near future. In the meantime, clients can access published data on all HuKemia models via HuBase™, CrownBio's proprietary database of PDX models.
For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.
Logo - http://photos.prnewswire.com/prnh/20160405/351602LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/crown-bioscience-announces-the-completion-of-over-100-blood-cancer-studies-300306171.html
SOURCE Crown Bioscience